ASX Share rice
Tue 04 Aug 2020 - 04:01:pm (Sydney)

CCE Share Price

CARNEGIE CLEAN ENERGY LIMITEDCCEUtilities

CCE Company Information

Name:

Carnegie Clean Energy Limited

Sector:

Utilities

Industry:

Utilities—Renewable

GIC Industry:

Independent Power and Renewable Electricity Producers

GIC Sub Industry:

Independent Power Producers & Energy Traders

Address:

21 North Mole Drive North Fremantle WA Australia 6159

Phone:

61 8 6168 8400

Chief Exec. Officer:

Mr. Jonathan Fievez BEng (Mecht)

Non Exec. Director & Company Sec.:

Mr. Grant Jonathan Mooney C.A., BBus, CA

Interim CFO & Commercial Mang.:

Ms. Rebecca Cutter

Chief Operating Officer:

Mr. David Kessel

Admin. Mang.:

Ms. Tegan Brookman Dip. Bus Mngt, Cert Iv Bus

Company Overview:

Carnegie Clean Energy Limited develops and commercializes the CETO wave energy technology for converting ocean wave energy into zero-emission electricity worldwide. It also produces and sells clean renewable energy using solar-battery systems to the Department of Defense. The company was formerly known as Carnegie Wave Energy Limited and changed its name to Carnegie Clean Energy Limited in December 2016. Carnegie Clean Energy Limited is based in North Fremantle, Australia.

CCE Share Price Information

Shares Issued:

11.14B

Market Capitalisation:

$11.14M

Revenue (TTM):

$495.19K

Earnings per Share:

$-0.035

Operating Margin (TTM):

$-6.64

Return On Assets (TTM):

$-0.08

Return On Equity (TTM):

$-0.27

Quarterly Revenue Growth (YOY):

-0.268

Gross Profit(TTM):

$357.74K

Diluted Earnings Per Share (TTM):

$-0.002

CCE CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-1,744,153

Change To Liabilities:

$-2,129,676

Total Cashflow From Investing Activities:

$-1,744,153

Net Borrowings:

$850K

Net Income:

$-51,930,513

Total Cash From Operating Activities:

$-4,383,412

Depreciation:

$250.99K

Change To Inventory:

$-464,937

Change To Account Receivables:

$-4,299,157

Capital Expenditures:

$79.71K

CCE Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-43,366,305

Net Income:

$-51,930,513

Gross Profit:

$357.74K

Operating Income:

$-4,872,125

Interest Expense:

$232.08K

Total Revenue:

$534.03K

Total Operating Expenses:

$5.23M

Cost Of Revenue:

$176.30K

CCE Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$15M

Total Liabilities:

$11.41M

Total Stockholder Equity:

$9.39M

Total Assets:

$20.80M

Common Stock:

$194.46M

Other Current Assets:

$200.87K

Retained Earnings:

$-185,970,443

Other Liabilities:

$49.48K

Other Assets:

$1.95M

Cash:

$255.61K

Total Current Liabilities:

$11.36M

Short-Term Debt:

$6.04M

Property - Plant & Equipment:

$2.68M

Net Tangible Assets:

$-5,609,191

Long-Term Investments:

$12.41K

Total Current Assets:

$1.17M

Net Receivables:

$142.89K

Short-Term Investments:

$19.63M

Accounts Payable:

$5.25M

Non Currrent Assets (Other):

$19.63M

Short-Term Investments:

$19.63

Non Current Liabilities Total:

$49.48K

CCE Share Price History

CCE News

29 Jul, 2020
AVITA Therapeutics, Inc. (NASDAQ: RCEL) (ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that management will present at the Canaccord Genuity 40th Annual Virtual Growth Conference on 12 August 2020 at 8:30 a.m. EDT.
13 Jul, 2020
AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that the Biomedical Advanced Research and Development Authority (BARDA), a part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), will procure the RECELL® System as part of the HHS mission to build preparedness for public health emergencies.
09 Jul, 2020
AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today preliminary unaudited results for the fourth quarter and full year ended June 30, 2020, together with a company update.
08 Jul, 2020
A look at the shareholders of AVITA Therapeutics, Inc. (ASX:AVH) can tell us which group is most powerful...
02 Jun, 2020
AVITA Medical Limited (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, today announced that it has submitted an Investigational Device Exemption (IDE) supplement with the U.S. Food and Drug Administration (FDA) for the initiation of a pivotal clinical trial to investigate the RECELL® System for the treatment of vitiligo.
21 May, 2020
AVITA Medical to Participate at the Jefferies Virtual Healthcare Conference
13 May, 2020
AVITA Medical to Participate at Oppenheimer's MedTech Summit
04 Nov, 2019
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...